Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 701–800 of 1,002
Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2− breast tumor cells
Zikry, T. M., Wolff, S. C., Ranek, J. S., Davis, H. M., Naugle, A., Luthra, N., Whitman, A. A., Kedziora, K. M., Stallaert, W., Kosorok, M. R., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309261121 · Cited by 35
“Data from multiple clinical trials show that combined antiestrogen and CDK4/6 inhibitor therapy nearly doubles progression - free survival, and many patients respond to CDK4/6 inhibitor therapy for several years (6, 16–18).”
MethodSlower CDK4 and faster CDK2 activation in the cell cycle
Zhang, W., Liu, Y., Jang, H., & Nussinov, R. (2024) · Structure · doi:10.1016/j.str.2024.04.012 · Cited by 31
Lipid metabolism involved in progression and drug resistance of breast cancer
Fu, W., Sun, A., & Dai, H. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101376 · Cited by 35
Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Cattrini, C., Zanardi, E., Vallome, G., Cavo, A., Cerbone, L., Meglio, A. D., Fabbroni, C., Latocca, M. M., Rizzo, F., Messina, C. G. M., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.08.009 · Cited by 33
Seidman, A. D., Bordeleau, L. J., Fehrenbacher, L., Barlow, W. E., Perlmutter, J., Rubinstein, L., Wedam, S. B., Hershman, D. L., Hayes, J. F., Butler, L. P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00242 · Cited by 30
The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
Stravodimou, A., & Voutsadakis, I. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14486 · Cited by 33
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
Kase, A. M., Copland, J. A., & Tan, W. W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266085 · Cited by 32
Saleem, F., Kanwal, Khan, K. M., Chigurupati, S., Andriani, Y., Solangi, M., Hameed, S., Hafez, A. A. M. A., Begum, F., Lodhi, M. A., et al. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103651 · Cited by 30
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 31
Li, N., Du, E. X., Chu, L.-H., Peeples, M., Xie, J., Barghout, V. E., & Tang, D. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351947 · Cited by 30
“arm had dose reductions due to an AE in a median followup of 23 months, and 82% of dose reductions were due to neutropenia and lowered neutrophil count [13].”
BackgroundRON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
Dustin, D. J., Gu, G., Beyer, A. R., Herzog, S. K., Edwards, D. G., Lin, H., Gonzalez, T. L., Grimm, S. L., Coarfa, C., Chan, D. W., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01174-z · Cited by 31
SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors
Cui, Y., Li, Y., Xu, Y., Liu, X., Kang, X., Zhu, J., Long, S., Han, Y., Xue, C., Sun, Z., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103304 · Cited by 35
“Recent advancements in biologically targeted therapies against cyclin-dependent kinase 4/6 (CDK4/6) have proven successful in delaying progression when added to endocrine therapy [3,4].”
BackgroundMohamed, A. M., Abou‐Ghadir, O. F., Mostafa, Y. A., Dahlous, K. A., Bräse, S., & Youssif, B. G. M. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1447618 · Cited by 30
“The use of palbociclib and letrozole in the treatment of advanced breast cancer is another example of successful combination therapy (Finn et al., 2016).”
Llombart‐Cussac, A., Harper-Wynne, C. L., Perelló, A., Hennequin, A., Fernández-Ortega, A., Colleoni, M. A., Marín, S., Quiroga, V., Médioni, J., Iranzo, V., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01865 · Cited by 70
Hamilton, E. P., Jeselsohn, R. M., Vahdat, L. T., & Hurvitz, S. A. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01137-5 · Cited by 32
“Despite improvements in progression-free survival (PFS) and overall survival (OS) [9–14], most patients inevitably develop treatment resistance and experience disease progression, leading to poor outcomes [4, 15, 16].”
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition
Suh, D. H., Kim, M., Kim, K., Kim, H. J., Lee, K.-H., & Kim, J. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e45 · Cited by 31
“PALOMA-2 trial was a phase III trial that was designed to confirm the phase II results of palbociclib plus letrozole versus letrozole alone as first-line therapy in postmenopausal women with ER-positive, HER2-negative advanced breast cancer [84].”
MethodDeng, Y., Ma, G., Li, W., Wang, T. I., Zhao, Y., & Wu, Q. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.017 · Cited by 36
CDK4-6 inhibitors in breast cancer: current status and future development
Choo, J. R.-E., & Lee, S. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541347 · Cited by 32
“Overall survival (OS) data are currently immature [14].”
BackgroundResultInfluentialAn evaluation of fulvestrant for the treatment of metastatic breast cancer
Soleja, M., Raj, G. V., & Unni, N. G. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1651293 · Cited by 29
Lee, J., Park, H. S., Won, H. S., Yang, J. H., Lee, H. Y., Woo, I. S., Shin, K., Hong, J. H., Yang, Y. J., Chun, S. H., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.451 · Cited by 29
“Furthermore, phase III trials covering firstline endocrine therapy plus CDK4/6 inhibitor [10,11,14] enrolled postmenopausal patients only, except MONALEESA-7 [18].”
BackgroundZhang, Y., Lun, X., & Guo, W. (2020) · Oncology Letters · doi:10.3892/ol.2020.12255 · Cited by 29
Gadsden, N. J., Fulcher, C. D., Li, D., Shrivastava, N., Thomas, C., Segall, J. E., Prystowsky, M. B., Schlecht, N. F., Gavathiotis, E., & Ow, T. J. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0915 · Cited by 30
“For instance, palbociclib is approved for treatment of ERþ/HER2 breast cancer in combination with anti-estrogen therapy (48).”
BackgroundMajor clinical research advances in gynecologic cancer in 2020
Lee, Y.-Y., Choi, M. C., Park, J., Suh, D. H., & Kim, J. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e53 · Cited by 31
“In estrogen receptor (ER) positive breast cancer, palbociclib combined with letrozole resulted in significantly longer progression free survival than that with letrozole alone [60].”
BackgroundTan, H., Cheung, P., Louie, A. V., Myrehaug, S. D., Niglas, M., Atenafu, E. G., Chu, W., Chung, H. T.-K., Poon, I., Sahgal, A., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.012 · Cited by 29
Badri, S. E., Tahir, B., Balachandran, K., Bezecny, P., Britton, F., Davies, D. M., DeSouza, K., Dixon, S., Hills, D., Moe, M., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.10.010 · Cited by 30
“This approval followed on from the results of the PALOMA-2 study which showed a signi fi cant improvement in progression-free survival (PFS) with palbociclib combined with letrozole compared with letrozole alone [6].”
Lee, S. H., Park, K., Kim, G. M., Jung, K. H., Kang, S. Y., Park, I. H., Kim, J. H., Ahn, H. K., Park, W., Im, S., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.01.014 · Cited by 29
“Recently the addition of cyclin dependent kinase 4 and 6 (CDK4/6) inhibitors to ET has been considered the standard therapy for most patients with HRþ, HER2- MBC regardless of menopausal status because of clinically meaningful increases in progression-free survival (PFS) [1,2] and overall survival (OS) [3e5].”
MethodSelf-citationDalenc, F., Lusque, A., Rouge, T. D. L. M., Pistilli, B., Brain, E. G. C., Pasquier, D., Debled, M., Théry, J., Gonçalvès, A., Desmoulins, I., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.031 · Cited by 29
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer
File, D. M., Pascual, T., Deal, A. M., Wheless, A., Perou, C. M., Dees, E. C., & Carey, L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06700-6 · Cited by 35
He, R., Yuan, X., Chen, Z., & Zheng, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109444 · Cited by 31
Nabieva, N., & Fasching, P. A. (2023) · Cancers · doi:10.3390/cancers15061763 · Cited by 29
“-3 [18,19] and MONALEESA-2, -3 and -7 [20–22] on average in percent.”
BackgroundBuller, W., Pallan, L., Chu, T., & Khoja, L. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231163121 · Cited by 33
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., & Pan, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119571 · Cited by 31
Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1796 · Cited by 32
Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
Gehrchen, M. L., Berg, T., Garly, R., Jensen, M., Eßer-Naumann, S., Rønlev, J. D., Nielsen, H. M., Knoop, A. S., & Kümler, I. (2024) · BJC Reports · doi:10.1038/s44276-024-00070-w · Cited by 32
Contemporary management of metastatic soft tissue sarcoma
Bui, N. Q., Wang, D. S., & Hiniker, S. M. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.06.005 · Cited by 29
Larsson, A.-M., Roxå, A., Leandersson, K., & Bergenfelz, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-49943-y · Cited by 29
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
Tamura, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz151 · Cited by 31
Iorfida, M., Mazza, M., & Munzone, E. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s196240 · Cited by 33
Chandarlapaty, S., & Razavi, P. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00090 · Cited by 29
taweraqi, N. A., & King, R. D. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04787-8 · Cited by 29
“to prolong progression-free survival when combined with hormone therapy [21, 22].”
BackgroundRen, H., Zhou, N., Ma, W., Zhang, P., Tu, D., Lu, C., & Yan, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10728 · Cited by 28
The G 1 -S transition is promoted by Rb degradation via the E3 ligase UBR5
Zhang, S., Valenzuela, L. F., Zatulovskiy, E. A., Mangiante, L., Curtis, C. N., & Skotheim, J. M. (2024) · Science Advances · doi:10.1126/sciadv.adq6858 · Cited by 27
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Hamid, A. B., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12040927 · Cited by 32
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., Llombart‐Cussac, A., & Cortés, J. (2020) · Cancers · doi:10.3390/cancers12092480 · Cited by 29
“Furthermore, this benefit was consistent across all patient subgroups [11,12].”
BackgroundLu, Y., Yang, S., Ho, Y., & Ji, Y. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1856 · Cited by 28
Drug induced vitiligo‐like depigmentation from a CDK 4/6 inhibitor
Chan, O. B., Su, J. C., Yazdabadi, A., & Chan, A. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13585 · Cited by 29
MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
Andrikopoulou, Α., Shalit, A., Zografos, E., Koutsoukos, K., Korakiti, A.-M., Liontos, M., Dimopoulos, M. A., & Zagouri, F. (2021) · Cancers · doi:10.3390/cancers13164114 · Cited by 29
García-Sáenz, J. Á., Martínez-Jáñez, N., Cubedo, R., Jerez, Y., Lahuerta, A., González-Santiago, S., Ferrer, N., Ramos, M., Alonso-Romero, J. L., Antón, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2652 · Cited by 30
Self-citationHajjo, R., Sabbah, D. A., Abusara, O. H., Kharmah, R., & Bardaweel, S. K. (2023) · Viruses · doi:10.3390/v15020568 · Cited by 29
Masurkar, P. P., Damgacioglu, H., Deshmukh, A. A., & Trivedi, M. V. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01245-y · Cited by 44
“In the absence of OS data for abemaciclib plus letrozole, we assumed that the OS rates of abemaciclib plus letrozole are similar to the OS rates of palbociclib plus letrozole [32] as both therapies share the same mechanism of action and have similar hazard ratios for the PFS benefit [19, 20].”
MethodPharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
Luca, A. D., Maiello, M. R., D’Alessio, A., Frezzetti, D., Gallo, M., Carotenuto, M., & Normanno, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1514720 · Cited by 28
“The randomized, double-blind phase III PALOMA-2 trial was designed to confirm and expand data from the PALOMA-1 study [33].”
BackgroundInfluentialIida, M., Tsuboi, K., Niwa, T., Ishida, T., & Hayashi, S. (2018) · Breast Cancer · doi:10.1007/s12282-018-0922-0 · Cited by 28
Kok, P., Beale, P., O’Connell, R. L., Grant, P., Bonaventura, T., Scurry, J., Antill, Y. C., Goh, J. C. H., Sjoquist, K. M., DeFazio, A., et al. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e86 · Cited by 28
“Why is it that only a subset of patients with ER+ EOC derive clinical benefit and that the duration of benefit is so much less than in women with advanced breast cancers? With emerging new therapeutics such as CDK 4/6 inhibitors (shown to double PFS in combination with AI) in advanced breast cancer [25] and inhibitors…”
Sammons, S. L., Shastry, M., Dent, S. F., Anders, C. K., & Hamilton, E. P. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.017 · Cited by 31
Montagna, E., & Colleoni, M. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919894105 · Cited by 28
Giannoudis, A., Malki, M. I., Rudraraju, B., Mohammed, H., Menon, S., Liloglou, T., Ali, S., Carroll, J. S., & Palmieri, C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01359-7 · Cited by 31
Tremblay, G., Chandiwana, D., Dolph, M., Hearnden, J., Forsythe, A., & Monaco, M. (2018) · Cancer Management and Research · doi:10.2147/cmar.s163478 · Cited by 28
“…Institute for Health and Clinical Excellence (NICE) 13 was conducted and identified 2 relevant Phase III RCTs and 1 relevant Phase II RCT: MONALEESA-2 12 , RIBO and LET (CLEE011A2301 Clinical Study Report, Novartis Data on File); PALOMA-2 20 , PALBO and LET; and PALOMA-1 10 , PALBO and LET.”
Royce, M., Shah, M., Zhang, L., Cheng, J., Bonner, M. K., Pegues, M. A., Miller, C. P., Leu, L., Price, L., Qiu, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1388 · Cited by 46
Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma
Yanagi, T., Kitamura, S., & Hata, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00079 · Cited by 27
“Cyclin-Dependent Kinase (Cdk) 16 in Cancer Cells Recently, Cdk4/Cdk6 inhibitor (palbociclib) showed promising results for metastatic breast cancer (39, 40).”
BackgroundZheng, J., Wu, J., Wang, C., Zhuang, S., Chen, J., & Ye, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233571 · Cited by 27
“As for combination schemes, 5 trials applied first-line ET strategy in our studies [12, 13, 15, 17, 19], and 4 trials included firstline and subsequent-line ET strategies simultaneously [14, 16, 18, 20].”
BackgroundMethodLu, Y., Lee, K. S., Chao, T.-Y., Tseng, L., Chitapanarux, I., Chen, S., Liu, C.-T., Sohn, J., Kim, J. H., Chang, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1008 · Cited by 27
“Treatment options for premenopausal patients with HR+, HER2–, advanced breast cancer (ABC [includes locally advanced and metastatic disease]) remain limited, and are mostly inferred from trials that enrolled postmenopausal women (7-12).”
BackgroundEziokwu, A. S., Varella, L., Kruse, M. L., Jia, X., Moore, H. C. F., Budd, G. T., Abraham, J., & Montero, A. J. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.09.010 · Cited by 28
Pepino, R. D. O., Coelho, F., Janku, T. A. B., Alencar, D. P., de Azevedo, W. F., & Canduri, F. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210329122147 · Cited by 27
Conley, C. C., McIntyre, M., Pensak, N. A., Lynce, F. C., Graham, D. M. A., Ismail-Khan, R. R., Lopez, K., Vadaparampil, S. T., & O’Neill, S. C. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06518-2 · Cited by 27
“CDK4/6 inhibitors have nearly doubled progression-free survival for patients with HR + MBC [7, 8] and increase overall survival in certain clinical subgroups [9, 10], even when accounting for dose delays and reductions [11].”
BackgroundTorres, A. Z., Nussbaum, N. C., Parrinello, C. M., Bourla, A. B., Bowser, B. E., Wagner, S., Tabano, D. C., George, D. J., & Miksad, R. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02091-8 · Cited by 34
Patt, D. A., Liu, X., Li, B. C., McRoy, L., Layman, R. M., & Brufsky, A. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.05.002 · Cited by 28
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
Lai, H.-Z., Han, J., Fu, X., Ren, Y., Li, Z., & You, F.-M. (2022) · Cancers · doi:10.3390/cancers14153774 · Cited by 31
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer
Cortesi, M., Zanoni, M., Maltoni, R., Ravaioli, S., Tumedei, M. M., Pirini, F., & Bravaccini, S. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2113513 · Cited by 28
“Several targeted therapies are currently used in clinics for hormone receptor-positive and HER2-positive BC with a significant benefit for the patients [3,4].”
BackgroundCardoso, F., Rihani, J., Harmer, V., Harbeck, N., Casas, A., Rugo, H. S., Fasching, P. A., Moore, A., de Courcy, J., Pathak, P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad207 · Cited by 29
Self-citationAromatase inhibitors: the journey from the state of the art to clinical open questions
Generali, D., Berardi, R., Caruso, M., Cazzaniga, M. E., Garrone, O., Minchella, I., Paris, I., Pinto, C., & Placido, S. D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249160 · Cited by 27
Abemaciclib for the treatment of breast cancer
Kotake, T., & Toi, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1448787 · Cited by 31
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Wu, J., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Yang, X., Lin, G., Lu, G., & Gong, F. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0483-x · Cited by 27
Jin, D., Tran, N., Thomas, N. J., & Tran, D. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223555 · Cited by 27
Breast Cancer: 45 Years of Research and Progress
Hortobágyi, G. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00199 · Cited by 27
Xue, Z., Lui, V. W. Y., Li, Y., Jia, L., You, C., Li, X., Piao, W., Yuan, H., Khong, P. L., Lo, K. W., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01763-z · Cited by 30
Thill, M., Zahn, M., Welt, A., Nusch, A., Zaiss, M. R., Engelken, K., Kaltenecker, G., Ringwald, K. G., Gratzke, K., Dille, S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35296 · Cited by 27
“The respective phase III studies showed nearly identical results of PFS for palbociclib, ribociclib and abemaciclib 2,5,6,21 and resulted in interchangeable first-line use of the CDKIs by the treating physicians.”
Self-citationGiugliano, F., Angelis, C. D., Pistilli, B., Viale, G., Bianchini, G., Giuliano, M., Malorni, L., Salimbeni, B. T., Espósito, A., Giordano, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102980 · Cited by 26
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines
Lopes-Ventura, S., Pojo, M., Matias, A. T., Moura, M. M., Marques, I. J., Leite, V. A. P. H., & Cavaco, B. M. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0947-4 · Cited by 25
Lynce, F. C., Blackburn, M. J., Zhuo, R., Gallagher, C., Hahn, O. M., Abu-Khalaf, M. M., Mohebtash, M., Wu, T., Pohlmann, P. R., Dilawari, A. A., et al. (2021) · Cancer · doi:10.1002/cncr.33620 · Cited by 26
“3623 Cancer October 1, 2021 The most common AE with palbociclib treatment in the clinical trial setting was neutropenia.(5,6) In a pooled analysis of the PALOMA trials, 80.”
Oshiro, H., Tome, Y., Miyake, K., Higuchi, T., Sugisawa, N., Kanaya, F., Nishida, K., & Hoffman, R. M. (2021) · Anticancer Research · doi:10.21873/anticanres.15115 · Cited by 26
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
Qayoom, H., Mehraj, U., Aisha, S., Sofi, S., & Mir, M. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100183 · Cited by 26
Kim, K. N., Shah, P. D., Clark, A. S., Freedman, G. M., Dastgheyb, S., Barsky, A. R., Dreyfuss, A. D., & Taunk, N. K. (2021) · The Breast · doi:10.1016/j.breast.2021.10.001 · Cited by 27
Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism
Zuo, Q., Park, N. H., Lee, J. K., & Madak‐Erdogan, Z. (2022) · Nutrients · doi:10.3390/nu14122376 · Cited by 29
PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity
Wang, S., Liu, X., Zhou, T., Li, J., Lin, Y., Zhou, A., Huang, J. M., Zhao, J., Cai, J., Cai, X., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00744-y · Cited by 26
Novel therapeutics in low-grade serous ovarian cancer
Cobb, L. P., & Gershenson, D. M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003677 · Cited by 28
Rugo, H. S., Liu, X., Li, B. C., McRoy, L., Layman, R. M., & Brufsky, A. (2023) · The Breast · doi:10.1016/j.breast.2023.03.015 · Cited by 26
“In these trials efficacy trends were relatively consistent across older and younger women [5,6].”
BackgroundResultSelf-citationKahraman, S., Erul, E., Seyyar, M., Gümüşay, Ö., Bayram, E., Demirel, B. Ç., Acar, Ö., Aksoy, S., Baytemür, N. K., Şahin, E., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1287 · Cited by 27
Mahdi, H., Ray-Coquard, I. L., Lorusso, D., Mirza, M. R., Monk, B. J., & Slomovitz, B. M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004454 · Cited by 27
Antonarelli, G., Salimbeni, B. T., Marra, A., Espósito, A., Locatelli, M., Trapani, D., Pescia, C., Fusco, N., Curigliano, G., & Criscitiello, C. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104148 · Cited by 27
DNA-PKcs suppresses illegitimate chromosome rearrangements
Wang, J., Sadeghi, C., & Frock, R. L. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae140 · Cited by 27
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102703 · Cited by 26
Hua, M., Xiong, F., Chong, S., Zhang, Z., Liu, Q., Hou, J., Zhang, Z., Gu, Z., Cui, X., Cui, Y., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102827 · Cited by 26
C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors
Ganeshapillai, D., Woo, L. W. L., THOMAS, M. P., Purohit, A., & Potter, B. V. L. (2018) · ACS Omega · doi:10.1021/acsomega.8b01383 · Cited by 28
Exaggeration of PFS by blinded, independent, central review (BICR)
Stone, A., Gebski, V., Davidson, R., Bloomfield, R., Bartlett, J. W., & Sabin, A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy514 · Cited by 26
“8 for the active arms of trials of abemociclib [20], palbociclib [21], respectively.”
BackgroundLi, X., Seebacher, N. A., Xiao, T., Hornicek, F. J., & Duan, Z. (2019) · Journal of Orthopaedic Research® · doi:10.1002/jor.24189 · Cited by 28
Pizzuti, L., Giordano, A., Michelotti, A., Mazzotta, M., Natoli, C., Gamucci, T., Angelis, C. D., Landucci, E., Diodati, L., Iezzi, L., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27832 · Cited by 26
Curigliano, G., de Azambuja, E., Lenihan, D. J., Calabró, M. G., Cardinale, D. M., & Cipolla, C. M. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0773 · Cited by 26
Reinhardt, F., Franken, A., Meier-Stiegen, F., Driemel, C., Stoecklein, N. H., Fischer, J., Niederacher, D., Ruckhaeberle, E., Fehm, T. N., & Neubauer, H. J. (2019) · Cancers · doi:10.3390/cancers11070903 · Cited by 26
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.